Dupilumab clinical trials, in English

Single center, randomly assigned, dummy treatment (placebo)- controlled study to assess change in mucociliary clearance of moderate to severe asthma patients after treatment with dupilumab or dummy treatment (placebo).

NCT04743791 · Official ClinicalTrials.gov record · Sally E. Wenzel MD

The skin microbiome plays a role in the pathogenesis of atopic dermatitis. However, it is unclear whether the range of microbiota on the skin is the cause or consequence of atopic skin inflammation.

NCT05099315 · Official ClinicalTrials.gov record · Charite University, Berlin, Germany

The main objective of the study is to assess how well it works and safety of dupilumab given up to 24 weeks in adults with CPUO. This is a master protocol which includes 2 parallel-treatment, neither you nor the study doctors know who gets the real treatment, 2- arm Phase 3 staggered studies of similar design (Study A and Study B) in male and female participants aged 18 to 90 years with CPUO.

NCT05263206 · Official ClinicalTrials.gov record · Sanofi

This is a prospective, randomly assigned, double blind, compared with a dummy treatment clinical trial. This trial will enroll a total of 68 patients with moderate to severe AA (affecting more than 50% of the scalp) at the time of screening with a targeted 54 subjects completers through Week 48.

NCT05551793 · Official ClinicalTrials.gov record · Emma Guttman

This study examines the effect of IL4RA blockade with dupilumab on the immune cells of atopic dermatitis skin lesions.

NCT05858619 · Official ClinicalTrials.gov record · University of California, San Francisco

This is a prospective, randomly assigned, neither you nor the study doctors know who gets the real treatment, compared with a dummy treatment clinical trial. This trial will enroll a total of 76 children and adolescents with moderate to severe AA (affecting at least 30% of the scalp) at the time of screening with a targeted 61 participants completing through Week 48.

NCT05866562 · Official ClinicalTrials.gov record · Icahn School of Medicine at Mount Sinai

This is a phase 1/2 study of combined treatment with dupilumab (anti-IL-4Ra) and cemiplimab (anti-PD-1) in patients with early-stage, resectable non-small cell lung cancer (NSCLC). The study will include participants with a confirmed diagnosis of NSCLC who are deemed to be surgical candidates, or patients who have a smoking history and radiographic findings highly suggestive if a diagnosis of NSCLC who are scheduled to undergo diagnostic biopsy.

NCT06088771 · Official ClinicalTrials.gov record · Icahn School of Medicine at Mount Sinai

In adolescents treated with dupilumab, clinical trials showed significant improvement of atopic dermatitis (AD) signs and symptoms, with a good safety profile. In these clinical trials, only patients with Eczema Area and Severity Index (EASI) score greater than or equal to (≥) 16 were enrolled, and effectiveness on sensitive/visible areas was not specifically evaluated.

NCT06192563 · Official ClinicalTrials.gov record · Sanofi

The goal of this study is to test the how well it works of Dupixent in improving post-burn itching symptoms versus the current standard of care.

NCT06226610 · Official ClinicalTrials.gov record · Akron Children's Hospital

This is a Phase 3, multicenter, open-label, pharmacokinetics (PK)/safety study. The study consists of 3 periods: * Screening period: 2 to 4 weeks.

NCT06293053 · Official ClinicalTrials.gov record · Sanofi

Background: Hypereosinophilic syndrome (HES) is a blood disorder that causes high levels of white blood cells called eosinophils. HES can damage the lungs and airways, intestines, skin, and other organs.

NCT06477653 · Official ClinicalTrials.gov record · National Institute of Allergy and Infectious Diseases (NIAID)

With a prevalence of 2-4% in western countries, Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) is of major concern regarding its substantial impact on the social and physical quality of life. So far, endoscopic sinus surgery remains the treatment of choice when the first line of medical treatment with corticosteroid has failed.

NCT06501807 · Official ClinicalTrials.gov record · University Hospital, Lille

This is a longitudinal, watch-and-measure (no experimental treatment required) non-treatment study (NIS) designed to characterize the patient population who receives dupilumab for eosinophilic esophagitis (EoE) treatment in a real-world setting in Germany with respect to their medical history, socio-demographic and disease characteristics, comorbidities (including type 2 inflammatory and atopic conditions), concomitant therapies and prior EoE treatments. Furthermore, this NIS aims to describe the long-term effectiveness of dupilumab for the treatment of EoE as assessed by the treating physician and reported by the patient, and its effect on health-related quality of life (HRQoL) during an individual watch-and-measure (no experimental treatment required) period of two years.

NCT06695897 · Official ClinicalTrials.gov record · Sanofi

This phase 1b/2a study evaluates the safety, feasibility, and how well it works of combining dupilumab (anti-IL-4Rα) and cemiplimab (anti-PD-1) in patients with early-stage, resectable NSCLC. Phase 1b focuses on safety and feasibility, using a 3+3 design to monitor dose-limiting toxicities (DLTs), while Phase 2a assesses the major pathological response (MPR) rate with a Simon's two-stage minimax design.

NCT06743581 · Official ClinicalTrials.gov record · Centre hospitalier de l'Université de Montréal (CHUM)

Asthma management has been revolutionised by the development of biological therapies. Dupilumab is an anti-interleukin4 receptor marketed in 2020 for severe asthmatic patients with 2 exacerbations or more within the last 12 months.

NCT06818019 · Official ClinicalTrials.gov record · University Hospital, Toulouse

The prevalence of Chronic Sinusitis with Nasal Polyps (CRSwNP) in the United States is estimated at roughly 4%, which equates to over 13 million Americans. Until recently, the only medical treatment options available for patients with CRSwNP were corticosteroids, with surgery reserved for medical failure.

NCT06824649 · Official ClinicalTrials.gov record · Medical University of South Carolina

The goal of this watch-and-measure (no experimental treatment required) study is to learn what can predict the return of the sense of smell in patients with chronic rhinosinusitis with nasal polyps being treated with dupilumab. The main questions it aims to answer are: 1.

NCT06892704 · Official ClinicalTrials.gov record · Northwestern University

LPS18583 is a multinational, randomly assigned, neither you nor the study doctors know who gets the real treatment, compared with a dummy treatment, parallel-group, Phase 4 study with 2 treatment groups. this study wants to assess the effect of dupilumab compared with dummy treatment (placebo) on airway inflammation, resistance, and remodeling including mucus plugging and its association with improvement on lung function, exacerbations, and quality of life improvement in participants aged 40 years of age up to 85 years of age (inclusive).

NCT07053423 · Official ClinicalTrials.gov record · Sanofi

This study is researching an experimental drug called dupilumab (called "study drug"). The study is focused on children with active eosinophilic esophagitis (EoE; an inflammatory disease of the esophagus) which impacts feeding and nourishment.

NCT07112378 · Official ClinicalTrials.gov record · Regeneron Pharmaceuticals

This Phase 1b/2 trial will measure the safety and how well it works of neoadjuvant immunotherapy in microsatellite stable (MSS) colorectal cancer (CRC) subjects with resectable liver metastases.

NCT07277322 · Official ClinicalTrials.gov record · Dan Feng

This study tests whether an asthma medication called dupilumab can help people achieve complete asthma control (called "remission") when given earlier in their disease, before asthma becomes severe. Currently, most people with asthma only receive advanced treatments like biologics after their condition has worsened significantly and caused lung damage.

NCT07309614 · Official ClinicalTrials.gov record · Université de Sherbrooke

The OBS19236 is a retrospective and prospective, non-treatment watch-and-measure (no experimental treatment required) study in COPD patients treated with dupilumab as part of routine clinical care. It will follow-up about 350 to 500 participants over 36 months in up to 50 sites in France.

NCT07380711 · Official ClinicalTrials.gov record · Sanofi

This is a a multicenter, randomly assigned, double-blinded, parallel, positive-controlled, Phase III comparative study to evaluate GS101 Injection versus Dupixent® in participants with moderate-to-severe atopic dermatitis. A total of 572 subjects are planned to be included and randomly assigned at a ratio of 1:1 to receive GS101 injection or Dupixent®

NCT07386743 · Official ClinicalTrials.gov record · Jiangsu Genscend Biopharmaceutical Co., Ltd

This study aims to assess the impact of dupilumab on the mental health and quality of life of moderate-to-severe Atopic Dermatitis (AD) patients. The study will recruit participants from AD patients who are already receiving dupilumab treatment.

NCT07467564 · Official ClinicalTrials.gov record · Sanofi

This study is researching a drug called dupilumab, referred to as "study drug". The study is focused on people diagnosed with COPD to determine if the study drug, in addition to standard of care treatment for COPD, might reduce the reoccurrence of a COPD exacerbation (a "flare-up") happening within the study treatment duration (around 90 days).

NCT07587658 · Official ClinicalTrials.gov record · Regeneron Pharmaceuticals

The STRIDE Registry will measure the real-world effectiveness and safety of dupilumab in participants with COPD. The primary objective is to describe characteristics of participants newly initiated with dupilumab for COPD.

NCT07612878 · Official ClinicalTrials.gov record · Sanofi

This study is expected to include approximately 520 patients with moderate to severe AD, and they will be randomly assigned to the treatment group (IBI3027) and the control group (Dupilumab Injection ) in a 1:1 ratio. Study period: It includes a screening period (4 weeks), a treatment period (44 weeks), and a follow-up period (8 weeks).

NCT07754786 · Official ClinicalTrials.gov record · Innovent Biologics (Suzhou) Co. Ltd.

Allogeneic hematopoietic stem cell transplantation (HSCT) is burdened with a high morbidity and mortality rates. Graft versus host disease (GVHD) is the clinical manifestation of an immune conflict.

NCT07771855 · Official ClinicalTrials.gov record · Hopital Foch

This study wants to find out how well tilrekimig works, how safe it is, and how it affects the body in adults and adolescents with moderate to severe atopic dermatitis (eczema). Eczema is a condition which can cause dryness, itching, and redness of your skin.

NCT07783425 · Official ClinicalTrials.gov record · Pfizer

This prospective, real-world watch-and-measure (no experimental treatment required) study (T2AIR Study) evaluates the long-term how well it works and safety of six biologics targeting Type 2 inflammation - omalizumab, mepolizumab, benralizumab, dupilumab, tezepelumab, and depemokimab - in patients with chronic airway diseases, including asthma and COPD under routine clinical practice in China. The primary objective is to determine the annualized exacerbation rate (AER) over 12 months of treatment.

NCT07823842 · Official ClinicalTrials.gov record · Shanghai Pulmonary Hospital, Shanghai, China

Atopic dermatitis is a chronic inflammatory skin disease associated with intense pruritus, recurrent eczematous lesions, sleep disturbance, and reduced quality of life. The disease may be influenced by genetic factors, environmental triggers, epidermal barrier dysfunction, and immune dysregulation.

NCT07904546 · Official ClinicalTrials.gov record · Universitätsklinikum Hamburg-Eppendorf

This study aims primarily to test target engagement of dupilumab by assessing changes in peripheral immune markers following interleukin-4 receptor alpha (IL-4Rα) blockade in adults with major depressive disorder (major depression). Secondary aims include evaluating safety, tolerability, feasibility, and open-label effects on depressive symptoms, blood-based immune markers, blood-brain barrier (BBB) function, and functional brain reward circuitry.

NCT07908563 · Official ClinicalTrials.gov record · Icahn School of Medicine at Mount Sinai